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Human cytomegalovirus (HCMV) causes severe diseases in those with immature 
or compromised immune systems, including transplant patients and congenitally infected 
infants.  Even in normal healthy adults, this virus has been linked to chronic diseases 
such as atherosclerosis and cancer.  Research has shown that HCMV is able to utilize a 
range of cellular signaling pathways to promote its replication. Sphingolipid signaling 
impacts several important physiological processes, including cell growth, migration, and 
survival (1).  Based on this, we hypothesized that sphingolipids are regulated by virus 
infection.  When we examined the accumulation of sphingolipids in cells infected with 
HCMV, we observed that sphingolipid metabolism is dynamically regulated according to 
the temporal phase of infection.  In this thesis, we set out to study the consequences of 
this regulation.  In these studies, we found that cells exposed to bioactive sphingolipids 
before infection show reduced synthesis of viral proteins.  These findings provide 




Human cytomegalovirus: HCMV is classified as herpesvirus 5, which is the 
prototype of the beta herpesvirus subfamily.  The herpesvirus family also includes viruses 
that cause oral and genital lesions (herpes simplex virus), chicken pox (varicella-zoster 
virus) and infectious mononucleosis (Epstein-Barr virus). HCMV infections are 
widespread within the human population with estimates ranging from 50-80% of the 
population as carrying this virus (5). Cytomegaloviruses share many characteristics with 
other herspesviruses, including the structure of the virus. The HCMV genome consists of 
a double-stranded linear DNA, which is enclosed in a capsid. The 230 kb genome 
includes both protein-coding and noncoding genes (3). Viral gene expression is organized 
in temporal phases. The immediate early genes are required for both early and late gene 
expression. The early genes encode for the factors that the virus requires for replication 
and the late gene expression occurs once the virus has begun replicating its genome and 
these genes encode for structural components of the virion. The capsid is surrounded by a 
tegument, and these components are then enclosed in envelope in which is inserted 
numerous viral glycoproteins (4). Another characteristic of HCMV and all human 
herpesviruses is that they establish a life-long infection. Initial or primary HCMV 
infections can be “silent,” meaning there are no signs or symptoms if infected or may 
manifest as symptoms that include fever, sore throat, fatigue, and swollen glands (4, 5). 
During primary infection, infectious virus can be isolated from saliva, urine, blood, 
semen, vaginal secretions, milk, and stool (4, 5). After primary infection, however, the 
virus establishes a state of clinical latency, in which the genome remains present in 
tissues, but infectious virus is no longer detectable.  During latency, the virus remains 
persistent at low-levels or in a quiescent latent state. In healthy adults, the virus is usually 
benign, but severe complications of HCMV infections are seen in immunosuppressed 
individuals, congenitally infected infants, and transplant recipients. These individuals can 
suffer from graft loss, vascular disease, hepatitis, pneumonitis, and growth retardation 
(4). Recent studies also provide evidence that HCMV infections are linked to chronic 
diseases such as atherosclerosis, coronary restenosis, and cancer (4). Currently, no 
effective vaccine is available to prevent HCMV infections.  There are five licensed 
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antiviral drugs known to treat HCMV, including ganciclovir, its prodrug valganciclovir, 
foscarnet, cidofovir, and formivirsen.  All except formivirsen, which is only licensed to 
treat infections of the eye, are known to cause toxicity to humans, and are not always 
effective due to emergence of drug-resistant strains.  Thus our ultimate goal is to find an 
effective treatment for this virus.   
F ig. 1. 
 
Sphingolipid metabolism and signaling. The 
biology of sphingolipids has advanced 
significantly in the past few years. 
Sphingolipids are present as constituents 
in membranes of all eukaryotic cells, and 
contribute to the protection of the cell 
against harmful environmental factors by 
the plasma membrane lipid bilayer (1, 6). 
More recently, sphingolipids have been 
shown to function as signaling molecules.   
Most work has focused on the bioactive 
sphingolipids, sphingosine-1-phosphate (S1P) and ceramide.  S1P, Figure 1A, is a polar 
sphingolipid metabolite which has been discovered to act both as an extracellular 
mediator via a family of G-protein-coupled receptors (GPCRs), S1P 1-5, and 
intracellularly as second messenger important for regulation of calcium homeostasis (6). 
S1P is synthesized in a variety of cells in response to a range of stimuli including growth 
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factors and cytokines.  S1P tends to promote cell survival, proliferation, differentiation, 
and migration, suppresses apoptosis, and may also have important pathophysiological 
roles in diseased states such as, atherosclerosis, cancer, and inflammation (6).  In 
addition, S1P is known to influence immune cell function and lymphocyte trafficking (2).  
S1P is produced from the phosphorylation of sphingosine, which is synthesized by the 
deacylation of ceramide in the degradative pathway of sphingolipid metabolism (6).  
Ceramide, Figure 1C (8), which serves as precursor for the synthesis of S1P is 
known to have opposing effects, which often lead to cessation of cell proliferation and 
apoptosis.  This suggests that inhibiting the conversion of ceramide into S1P may induce 
cell death in diseases, such as cancer (6).  Ceramide is synthesized in the de novo 
pathway. 
Dihydrosphingosine-1-phosphate (dhS1P), Figure 1B, is similar to S1P and 
differs only in that it lacks the 4, 5-trans double bond, as shown in Figure 1A and B.  
Dihydrosphingosine-1-phosphate is produced from the phosphorylation of 
dihydrosphingosine, which is an intermediate of the de novo pathway (1). Altogether, 
much less is known about the biological activity of dhS1P, though it is presumed to use 
the same receptors as S1P.  
In previous studies, it was established that HCMV modulates lipid-signaling 
pathways (2).  In this study, we set out to explore the consequences of this modulation. 
This area of research brings us great fascination considering how little is known 
regarding the role of lipids in virus infection. Ultimately, further research in this area may 
suggest novel treatments for viral diseases. A recent publication by the laboratories of Dr. 
Joanne Trgovcich and Dr. James Van Brocklyn demonstrated that sphingolipid 
metabolism is dynamically regulated by HCMV infection (2). Specifically, it was 
observed that levels of the bioactive lipid dhS1P were elevated at early times of infection, 
suggesting activation of the de novo pathway of sphingolipid metabolism.  Activation of 
the de novo pathway appears to promote viral gene expression during the immediate 
early temporal phase of infection.  At later times of infection, the levels of both S1P and 
dhS1P were decreased. In this study, we wanted to explore more fully the consequence of 
decreased bioactive lipids observed at later times of infection.  This decrease in S1P and 
dhS1P abundance may represent a cellular response to infection.  Alternatively, it may 
represent a viral strategy to optimize growth or spread.  To begin to determine the 
biological significance of these observations, we performed studies to activate 
sphingolipid-signaling pathways prior to infection.  
 We observed that viral protein accumulation was reduced when cells pre-treated 
with S1P and dhS1P were infected with HCMV.  This led us to hypothesize that 
activation of sphingolipid receptors may contribute to cellular antiviral responses.  Next, 
we set out to test if this involved activation of genes associated with antiviral defense, 
namely, interferon-stimulated genes (ISGs).  We provide very preliminary data 
suggesting that antiviral genes can be up-regulated by activation of lipid signaling 
pathways.  However, much more work needs to be done to establish the mechanism that 




Cell Culture and infection.  MRC-5 human primary fibroblasts were obtained 
from ATCC. MRC-5 cells were preserved in modified Eagle’s medium supplemented 
with 10% fetal calf serum, 1.7mM sodium bicarbonate, 1.4mM sodium chloride, essential 
and non-essential amino acids, vitamins, and sodium pyruvate at manufacturers’ 
recommended concentrations (Sigma). Cells were passed weekly by trypsin digestion at a 
ratio of 1:3 and used in experiments at passages 5-7. Cells were maintained at 37 ºC in 
95% air, 5% CO2 (2, 12). MRC-5 cells were serum-starved for 48 hours prior to infection. 
Prior to infection, 24 hours,  9 six-well plates containing MRC-5 cells were pretreated 
with 1000nM of dhS1P, 1000nM of S1P, and vehicle alone (DMEM containing 10% 
fatty acid-free bovine serum albumen). Cells were then exposed to1.0 or 0.5 plaque-
forming units per cell (PFU/cell) of HCMV strain AD169, which was purchased from 
ATCC. 
Plaque Assay: MRC-5 cells were serum-starved for 48 hours prior to infection. 
Prior to infection, 24 hours, 9 six-well plates containing MRC-5 cells were pretreated 
with 1000nM of dhS1P, 1000nM of S1P, and vehicle alone (DMEM containing 10% 
fatty acid-free bovine serum albumen). Cells were then exposed to1.0 or 0.5 plaque-
forming units per cell (PFU/cell) of HCMV, which is diluted in medium containing 1% 
serum of 199V. At 0 and 96 hrs after infection, cells were then scraped, sonicated, and 
subjected to freeze and thaw.  Virus titers were determined in MRC-5 cells by standard 
plaque assay (2). Briefly, lysates were used as inoculums in fresh MRC-5 cells.  After the 
infection period, cells were overlaid with 1% solution of agarose (SeaKem LE, FMC 
Corp.) in dH20 and 1X B medium.   Plates were fixed by adding 3 mL of 10% neutral 
buffered formalin per well and the agar was gently pulled away from the plastic. Plates 
were then air dried and stained with 0.1% crystal violet prepared in 25% methanol. The 
stain was then removed and washed gently with water.   
Lipid and Drug Treatment:  Prior to infection, 24 hours, six-well plates containing 
MRC-5 cells were pretreated with 1000nM of dhS1P, 1000nM of S1P, 100 units (U) of 
interferon beta as a positive control, vehicle alone (10% fatty acid-free bovine serum 
albumen) as a negative control, or 20ug/mL of FTY720, or the vehicle for FTY720, 
dimethylsulfoxide (DMSO).  FTY720 is both an agonist and antagonist of the S1P 
receptor that binds to the receptor and leads to its down regulation from the cell surface.  
Immunoblotting:  At 24, 48, and 72 hours (hrs) after infection, cells were 
disrupted in lysis buffer containing Triton X-100, 50 mM Tris, 150 mM NaCl and 1% 
(v/v) protease inhibitor mixture (Sigma). Proteins in cell lysates were separated by size 
using denaturing polyacrylamide gel electrophoresis (SDS-PAGE) and 
electrophoretically transferred to a nitrocellulose membrane.  The abundance of viral 
proteins, immediate early protein 1 (IE1), UL44, pp150, and the cellular protein 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (used as a loading control), was 
then analyzed by immunoblot analysis by using specific antibodies and visualized by 
chemiluminescence and exposure to film.  The viral proteins were chosen based on the 
fact that they are representative proteins of different temporal phases of infection 
including immediate early (IE1), early (UL44), and late (pp150). 
Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR): Reverse 
transcription PCR was performed as described by ThermoScript RT-PCR System 
according to manufactures instructions (Invitrogen).  MRC-5 cells were pretreated with 
1000nM of S1P and dhS1P and 100 units (U) of interferon. RNA was then harvested at 6 
and 24hrs after treatment. RNA was extracted from cultured cells using Trizol Reagent 
(Invitrogen) according to manufacturer’s instructions, followed by treatment of DNase 1 
for 15 min at 37°C. cDNA was created using ThermoScript RT-PCR System (Invitrogen) 
according to manufacture’s instructions.  PCR reactions were setup using ThermoScript 
System (Invitrogen). PCR analysis was performed for 30 cycles using 60 °C for 
annealing and 72°C for extension.  PCR products were observed by agarose gel 
electrophoresis. Primer sequences purchased from Integrated DNA Technologies (IDT) 





Real Time Quantitative PCR:  Real time PCR analysis was performed by total 
RNA extraction using Trizol (Invitrogen, Carlsbad, CA), followed by DNase treatment 
according to manufactures instructions (Ambion, Austin, TX), using 100ng of RNA per 
reaction. cDNA was created using the 5x cDNA synthesis buffer (Invitrogen) according 
to manufacturers instructions.  PCR reactions were set up using Taqman® Universal PCR 
Master Mix (Applied Biosystems, Foster City, CA). Real time PCR analysis was 
performed using BioRad iCycler Sequence Detection System Instrument for 40 cycles. 
(7).  
Primer sequences of Applied Biosystems Assays-on-Demand™ gene expression 
assays are proprietary, though RefSeq accession numbers for genes, location of binding 
sites for fluorescent probes, and amplicons are as follows: ISG56 (catalog # 
HS01675197_m1) based on RegSeq NM001548.3. Probe was located at base 76, exon1/ 
exon2 boundary. Oligoadenylate synthetase-like (OASL) (catalog # HS00984390_m1) 
based on RefSeq NM198213.1. Probe was located at base 811, exon4/exon5 boundary.  
GAPDH (catalog # HS99999905_m1) based on RefSeq NM.002046.3 Probe was located 
at base 157, exon3/exon3 (7). 
 
Results 
 Activation of sphingolipid signaling pathways reduces viral protein accumulation. 
Previously, it was shown that at early times after infection, dhS1P levels are elevated in 
infected cells but, at later times, both S1P and dhS1P levels were decreased (data not 
shown).  To begin to investigate this decrease in bioactive sphingolipids at late times, we 
activated sphingolipid signaling prior to infection.  Our initial step was to measure viral 
protein accumulation in cells previously exposed to S1P and dhS1P. MRC-5 cells were 
first treated with 1000nM of each lipid then exposed to 0.5 PFU per cell of AD169 strain 
of HCMV. Cells were harvested on a time course of 24, 48, and 72hrs. The cells were 
then solubilized and assayed by immunoblotting. As shown in figure 2, we observed a 
decreased accumulation of viral proteins IE1, UL44, and pp150 when pretreated with S1P 
and dhS1P.  In total, we performed four experiments showing consistent results for UL44 
and pp150.  IE1 levels were reduced in 2 out of 4 experiments.  Further studies are 
needed to determine if the effect of these bioactive lipids on IE1 is related to confluency 
of cells or the multiplicity of infection. The observation that IE1 levels recover at late 
times may be indicative that the lipids have the greatest effect at early times when viral 
replication occurs. Based on these observations, we suggested that S1P and dhS1P  
F ig. 3. G rowth curve analysis. The graph depicts 
PFU/mL between vehicle, S1P and dhS1P for 0 and 96 





signaling activates antiviral responses in cells.
 












One Step Growth Curve Analysis in Cells Pre-Treated with Bioactive 
Sphingolipids. In order to determine if the decrease in viral protein accumulation will 
translate into a decrease in virus growth, we performed a one-step growth-curve study in 
MRC-5 cells pre-treated with S1P and dhS1P. MRC-5 cells were first treated with 1000 
nM of each lipid then exposed to 1.0 PFU per cell of AD169 strain of HCMV. Cells were 
then scraped, sonicated, and subjected to freeze and thaw at 0 and 96 hours after 
F ig. 2. Pre-treatment of M R C-5 cells with S1P and 
dhS1P showed a decreased accumulation of viral 
proteins.  Film image of immunoblot of viral proteins 
immediate early (IE1), early (UL44), late (PP150) and 
the cellular protein (GAPDH) from lysates of cells 
treated with vehicle (v), dhS1P (dh), or S1P (s) at 
various times of infection, 24, 48 and 72hrs.The viral 
proteins chosen are based on the fact that they 
representative of different temporal phases of infection. 
    
    
 
infection. These lysates were used as inoculums in a plaque assay.  As shown in figure 3, 
we did not observe a significant change between virus growth in cells exposed to vehicle, 
S1P, and dhS1P, although we do see a slight decrease for S1P. We conclude that under 
these conditions, pretreatment of cells with S1P and dhS1P does not reduce viral growth 
in vitro. It may be that the virus is able to overcome the effects of these bioactive lipids at 
later times of infection.   However, it is also important to note that many viral mutants 
that show no growth defects in vitro exhibit severe defects in vivo.  Therefore, it may still 
be useful to perform in vivo studies using the mouse model of CMV infection. 
Bioactive sphingolipid signaling may lead to induction of interferon-stimulated 
genes known to possess antiviral activity.  After examining a decrease in viral protein 
accumulation, our next step was to investigate the mechanism by which sphingolipid 
treatment affected viral protein production. One possible explanation for the decrease in 
accumulation of viral proteins is that activation of signaling pathways mediated by 
bioactive sphingolipids leads to the direct induction of antiviral gene expression or the 
induction of interferons, which would indirectly activate antiviral gene expression.  To 
test this, cells were pretreated with S1P, dhS1P, and interferon beta as previously stated. 
RNA was then harvested for 6 and 24hrs and RT-PCR was carried out as described. 
Figure 4 demonstrates that, upon treatment of S1P and dhS1P, there is expression of 
interferon-stimulated gene 56 (ISG56) in cells treated with dhS1P, but not S1P. Also, 
these results were not completely conclusive due to a low level of expression in our 
negative control, vehicle-treated MRC-5 cells. Given these results, we question if there is 
a low level of expression of ISG56 normally observed in MRC-5 fibroblasts. Thus, in 
order to confirm our results, our next step was to carry out Real Time Quantitative PCR 
 
   L          V       dh      S1P    INF      NT F ig. 4. Possible ISG induction at lipid 
treatment:  Digital Image of agarose gel used to 
separate PCR products specifically for ISG56 
transcripts. MRC-5 cells in six-well tissue culture 
plates after serum starved were pre-treated with 
1000nm of dhS1P, S1P and 100 units interferon. 
After treatment cells were harvested at 6 h. Total 
RNA was isolated. RT-PCR of ISG56 transcripts 
identified. Labels are as followed: L-ladder, dh-
dhS1P, S1P-S1P, INF-interferon, NT-no test (cell 
only) 
 
to more precisely quantitate levels of ISGs 6 hrs after exposure to S1P and dhS1P.  A 
preliminary experiment is shown in Figure 5 and Table 1. In this experiment, we 
amplified GAPDH in samples in which reverse transcriptase (RT+) was included but not 
those in which RT was omitted indicating we did not have DNA contamination.  We 
could only amplify ISG56 in cells treated with INF and even here only at a very high Ct 
cycle.  This indicates this probe is not sensitive enough at the template levels used in 
these reactions.  We could amplify OAS in INF-treated cells as well as cells treated with 
S1P and dhS1P, although again the Ct values were very high.  We conclude we need to 
repeat these studies with better probes or with more templates.  However, these 
preliminary findings generally support the notion that ISG induction may be a 






























F igure 5. PC R Amplification/Cycle 
G raphs.  Cells were exposed to the 
indicated lipids and RNA was isolated 
6 hrs after treatment and subjected to 








Over the past few years, it has become clear that sphingolipids are key signaling 
molecules. From our previous studies, we show evidence that sphingolipids are 
modulated during infection of HCMV. In this study, we show the following results: (1) 
There is a decreased accumulation of viral proteins IE1, UL44 and pp150 in cells 
exposed to S1P and dhS1P prior to infection; (2) This decrease does not cause a 
substantial decrease in viral growth in vitro, though there is a very slight decrease in viral 
growth in cells pre-treated with S1P; (3) there is a possible induction of the interferon-
induced genes, ISG56 and OAS, in cells pre-treated with S1P and dhS1P. 
Earlier studies performed by our laboratory demonstrated that sphingolipid metabolism is 
regulated dynamically by HCMV infection. At early times of infection, 24 hrs, we did not 
observe a significant change in S1P between mock-infected cells and HCMV-infected 
cells, although we did see a drastic increase in dhS1P, which was indicative of a viral 
strategy to optimize growth and also suggests that de novo sphingolipid synthesis is 
stimulated by HCMV during 24 hrs of infection and is later decreased (2).  The data 
specifically illustrated that levels of the bioactive lipids S1P and dhS1P were diminished 
at later times of infection. This may represent a cellular response to infection.  
Alternatively, it may represent a viral strategy to optimize growth or spread.   
 In our current study, we aimed to determine why we saw a decrease at late times 
of infection. In order to test this phenomenon, we looked at the accumulation of viral 
proteins in cells exposed to S1P and dhS1P before infection. Interestingly, we saw that 
there was a decreased accumulation of IEI, UL44, and pp150 during the three phases of 
infection. These results alluded to an antiviral activity of bioactive sphingolipids. This 
guided us to our next step, which was to learn the mechanism by which bioactive lipids 
may exert antiviral activity.  
 A common cellular response to challenges against viral infection, parasites, or 
foreign invaders is the production of interferon’s (IFNs), which belong to a class of 
glycoproteins known as cytokines. These natural cell-signaling proteins, aide in inhibiting 
viral replication in cells, inducing resistance of cells to viral infection and ultimately 
cellular defense mechanisms against viruses. Thus, our initial strategy to learn the 
mechanism used by the lipids was to look at induction of interferon-stimulated genes 
(ISGs). We specifically looked at ISG56, a known antiviral gene. From our data, we 
demonstrated that dhS1P, but not S1P, induced ISG56, although we can not conclude if 
this is a direct approach of the lipids acting on GPCRs to stimulate ISGs, or an indirect 
effect by means of the interferon pathway. In order to answer these questions, we began 
to look with quantitative PCR. Although not conclusive, the quantitative PCR suggests 
that OAS is induced by S1P and dhS1P. From preliminary results, we conclude the 
necessity to improve the assay conditions and for a more detailed time-course experiment 
to establish whether activation of S1P and dhS1P signaling directly or indirectly (through 
interferons) stimulates antiviral gene expression.  
 Overall we conclude that sphingolipid metabolism is dynamically regulated upon 
HCMV infection. We have shown a novel idea that sphingolipids are known to possess 
antiviral activity, yet further research is needed in order to understand the differences 
seen at early and late time points, as well as the mechanistic approach used by these 
bioactive sphingolipids. We have only begun to understand the significance of 
sphingolipids, though future studies will help us answer if sphingolipid synthesis is a 
method used by the virus to regulate replication, or a cellular mechanism to antagonize 
virus growth. Our future aims for this study include the following: 
1. To test the hypothesis that bioactive sphingolipids activate expression of 
interferon-induced genes by specifically analyzing other interferon-stimulating 
genes including ISG54 and oligo 2A synthetase. We also need to improve the RT-
PCR method and analyze later time points. We will also repeat this experiment in 
the presence of neutralizing antibodies to interferons.  
2. Preliminary results do not show a decrease in virus growth, although early time 
points need to be analyzed. We would also like to test the hypothesis that 
activation of sphingolipid signaling pathways will impair not only HCMV protein 
production, but also virus replication using a plaque reduction assay.  
3. To test the hypothesis that exposing cells to these bioactive sphingolipids elicits a 
general antiviral virus replication.  This is an RNA virus with very different 
properties from the DNA response by measuring Sindbis virus protein 
accumulation and herpes viruses. 
 Together these studies will help us learn more about the biology of sphingolipids 
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